Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
艾吉納斯宣佈將在即將舉行的美國臨床腫瘤學會胃腸癌症研討會上進行五個關於Botensilimab(Bot,一種Fc增強型抗CTLA-4抗體)加Balstilimab(Bal,一種抗PD-1抗體)的展示。
Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
在即將舉行的美國臨床腫瘤學會胃腸道癌症研討會上,Agenus宣佈了五場演講,其中包括Botensilimab(Bot,一種增強型抗CTLA-4抗體)和Balstilimab(Bal,一種抗PD-1抗體)